Attovia Therapeutics

Update in progress

ATTO (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Attovia Therapeutics, Inc. is a clinical-stage biopharma company in San Carlos, California, developing immune‑mediated disease therapies in the United States. Using its ATTOBODY biparatopic platform, it creates novel biotherapeutics. Lead agents include ATTO-1310 (IL‑31 inhibitor for chronic pruritus), ATTO-2306 (IL‑13/IL‑31 inhibitor for atopic and skin diseases), and ATTO-1091 (TL1A/IL‑23/integrin a4ß7 triple inhibitor for IBD).

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.55; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive